terça-feira, 6 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· July 13, 2026

Solitron Devices, Inc. Announces Fiscal 2027 First Quarter Results

View original at globenewswire.com
Solitron Devices, Inc. Announces Fiscal 2027 First Quarter Results WEST PALM BEACH, Fla., July 13, 2026 (GLOBE NEWSWIRE) -- Solitron Devices, Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Net income in the fiscal 2027 first quarter was impacted by a $0.33 million increase to the contingent consideration related to the MEI earn-out payment, based on a large order received after the end of the fiscal quarter.

    60% confidence
  • Revenue is expected to continue at the fiscal Q1 2027 level or greater for the remainder of fiscal year 2027, driven by strong backlog.

    60% confidence
  • No actual income taxes were due despite the income statement reflecting income tax expense, because the Company has deferred tax assets from previous net operating losses.

    60% confidence
  • There is no assurance that the strategic alternatives review will result in a merger, sale, acquisition, tender offer, or special dividend, and the Company will not make further announcements until the Board approves a specific course of action.

    60% confidence
  • Defense procurement processes tend to move slowly.

    60% confidence
  • The next AMRAAM order is currently expected in the fiscal third quarter.

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com